-
Life Sciences Expertise
Seth represents pharmaceutical, biotechnology, medical device, diagnostic, and other technology-based companies in a wide range of strategic transactions and corporate matters.
-
Extensive In-House Transactional Experience
Seth has more than 16 years of experience serving as in-house counsel at a global pharmaceutical company, where he advised on an array of strategic transactions and managed a team of lawyers and business professionals responsible for implementing intellectual property and business development transactions.
Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.
Prior to joining the firm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he trained and managed a team of lawyers and business professionals responsible for implementing the company's global business development transactions. In this role, Seth counseled on strategic transactions, structuring, negotiating, and drafting strategic collaboration agreements, licensing agreements, research and development agreements, co-promotion agreements, commercialization agreements, option agreements, material transfer agreements, clinical trial agreements, CRO agreements, distribution agreements, manufacturing and supply agreements, and other transactions. He also has experience with public and private M&A transactions, and has advised on antitrust issues and filings, FINRA inquiries, SEC filings, and corporate governance matters.
Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New York. Previously, he was general counsel at H&H Bagels, corporate counsel at Thompson Medical Company and Slim Fast Foods Company, and an associate at D'Erasmo, Shure & Perez in Rockville, Maryland.
Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.
Prior to joining the firm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he trained and managed a team of lawyers and business professionals responsible for implementing the company's global business development transactions. In this role, Seth counseled on strategic transactions, structuring, negotiating, and drafting strategic collaboration agreements, licensing agreements, research and development agreements, co-promotion agreements, commercialization agreements, option agreements, material transfer agreements, clinical trial agreements, CRO agreements, distribution agreements, manufacturing and supply agreements, and other transactions. He also has experience with public and private M&A transactions, and has advised on antitrust issues and filings, FINRA inquiries, SEC filings, and corporate governance matters.
Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New York. Previously, he was general counsel at H&H Bagels, corporate counsel at Thompson Medical Company and Slim Fast Foods Company, and an associate at D'Erasmo, Shure & Perez in Rockville, Maryland.
- J.D., Loyola Law School, 1994
- B.S., Finance, New York University Leonard N. Stern School of Business, 1991
- State Bar of New Jersey
- State Bar of New York
- J.D., Loyola Law School, 1994
- B.S., Finance, New York University Leonard N. Stern School of Business, 1991
- State Bar of New Jersey
- State Bar of New York
Illustrative Representations
Pharmaceutical and Diagnostic Collaboration Agreements
- PaciraBioSciences on its license agreement with AmacaThera for AMT-143, an investigational long‑acting formulation of the non‑opioid analgesic ropivacaine for postsurgical pain control
- Revival Healthcare Capital on its strategic partnership with Olympus Corporation aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal treatments
- Cyrano Therapeutics on its option agreement with KYORIN Pharmaceuticals for CYR-064, a novel treatment for hyposmia
- Cimeio Therapeutics on its research collaboration with Kyowa Kirin
- Aytu BioPharma on its exclusive collaboration, distribution, and supply agreement with Lupin Pharma Canada Ltd
- Ripple Therapeutics on its collaboration and option-to-license agreement with AbbVie
- BigHat Biosciences on its research collaboration with AbbVie
- Related Sciences on its drug discovery collaboration with Charles River
- Daiichi Sankyo on its global development and commercialization collaboration with AstraZeneca for TROP2-directed antibody drug conjugate (ADC) DS-1062*
- Daiichi Sankyo on its strategic coalition with CRO Syneos Health to develop an ADC oncology pipeline*
- Daiichi Sankyo on its global development and commercialization collaboration with AstraZeneca for HER2-directed ADC DS-8201 (Enhertu®)*
- Daiichi Sankyo on its clinical trial combination agreement with Merck for DS-1062 and Keytruda® and with Bristol-Myers Squibb for DS-8201 (Enhertu®) and Opdivo®*
- Daiichi Sankyo on its strategic collaboration in Japan with Kite Pharma Inc. for a cell therapy product (Yescarta®)*
- Daiichi Sankyo on multiple collaboration agreements with Portola Pharmaceuticals and with Perosphere (acquired by AMAG) for factor Xa reversal agents*
- Daiichi Sankyo on its strategic collaboration and co-promotion agreement with AstraZeneca for a small molecule product for opioid-induced constipation (Movantik®)*
- Daiichi Sankyo on its strategic collaboration and option agreement with Amplimmune (acquired by AstraZeneca) for an immune modulation therapy*
- Daiichi Sankyo on its exclusive licensing agreement in Japan with Coherus Biosciences for select biosimilars*
- Daiichi Sankyo on multiple exclusive worldwide licensing agreements with ArQule (acquired by Merck) for small molecule oncology products*
- Daiichi Sankyo on its authorized generic distribution agreements with Ranbaxy Pharmaceuticals and Sun Pharmaceuticals*
- Daiichi Sankyo on its global collaboration with Invivoscribe and other prominent diagnostic companies for companion diagnostics*
- Daiichi Sankyo on its research collaboration with DarwinHealth*
- Daiichi Sankyo on its multiple alliance agreements with Sanford-Burnham Medical Research Institute*
- Venture Science Laboratories on its drug discovery research collaboration with University of California San Francisco (UCSF) to develop novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases*
Mergers and Acquisitions and Divestitures
- IVIVA on its acquisition by United Therapeutics
- Plexxikon on its sale of a portfolio of small molecule oncology therapeutics and other assets to Opna Bio*
- Daiichi Sankyo on the divestiture of its pharmaceutical packaging plant and laboratory to Sharp Packaging Services, a division of UDG Healthcare*
- Daiichi Sankyo on its acquisition of Ambit Biosciences*
- Daiichi Sankyo on its sale of Ranbaxy Laboratories to Sun Pharmaceuticals *
- Daiichi Sankyo on its acquisition of Plexxikon*
*Denotes experience prior to joining Wilson Sonsini in 2022.
Illustrative Representations
Pharmaceutical and Diagnostic Collaboration Agreements
- PaciraBioSciences on its license agreement with AmacaThera for AMT-143, an investigational long‑acting formulation of the non‑opioid analgesic ropivacaine for postsurgical pain control
- Revival Healthcare Capital on its strategic partnership with Olympus Corporation aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal treatments
- Cyrano Therapeutics on its option agreement with KYORIN Pharmaceuticals for CYR-064, a novel treatment for hyposmia
- Cimeio Therapeutics on its research collaboration with Kyowa Kirin
- Aytu BioPharma on its exclusive collaboration, distribution, and supply agreement with Lupin Pharma Canada Ltd
- Ripple Therapeutics on its collaboration and option-to-license agreement with AbbVie
- BigHat Biosciences on its research collaboration with AbbVie
- Related Sciences on its drug discovery collaboration with Charles River
- Daiichi Sankyo on its global development and commercialization collaboration with AstraZeneca for TROP2-directed antibody drug conjugate (ADC) DS-1062*
- Daiichi Sankyo on its strategic coalition with CRO Syneos Health to develop an ADC oncology pipeline*
- Daiichi Sankyo on its global development and commercialization collaboration with AstraZeneca for HER2-directed ADC DS-8201 (Enhertu®)*
- Daiichi Sankyo on its clinical trial combination agreement with Merck for DS-1062 and Keytruda® and with Bristol-Myers Squibb for DS-8201 (Enhertu®) and Opdivo®*
- Daiichi Sankyo on its strategic collaboration in Japan with Kite Pharma Inc. for a cell therapy product (Yescarta®)*
- Daiichi Sankyo on multiple collaboration agreements with Portola Pharmaceuticals and with Perosphere (acquired by AMAG) for factor Xa reversal agents*
- Daiichi Sankyo on its strategic collaboration and co-promotion agreement with AstraZeneca for a small molecule product for opioid-induced constipation (Movantik®)*
- Daiichi Sankyo on its strategic collaboration and option agreement with Amplimmune (acquired by AstraZeneca) for an immune modulation therapy*
- Daiichi Sankyo on its exclusive licensing agreement in Japan with Coherus Biosciences for select biosimilars*
- Daiichi Sankyo on multiple exclusive worldwide licensing agreements with ArQule (acquired by Merck) for small molecule oncology products*
- Daiichi Sankyo on its authorized generic distribution agreements with Ranbaxy Pharmaceuticals and Sun Pharmaceuticals*
- Daiichi Sankyo on its global collaboration with Invivoscribe and other prominent diagnostic companies for companion diagnostics*
- Daiichi Sankyo on its research collaboration with DarwinHealth*
- Daiichi Sankyo on its multiple alliance agreements with Sanford-Burnham Medical Research Institute*
- Venture Science Laboratories on its drug discovery research collaboration with University of California San Francisco (UCSF) to develop novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases*
Mergers and Acquisitions and Divestitures
- IVIVA on its acquisition by United Therapeutics
- Plexxikon on its sale of a portfolio of small molecule oncology therapeutics and other assets to Opna Bio*
- Daiichi Sankyo on the divestiture of its pharmaceutical packaging plant and laboratory to Sharp Packaging Services, a division of UDG Healthcare*
- Daiichi Sankyo on its acquisition of Ambit Biosciences*
- Daiichi Sankyo on its sale of Ranbaxy Laboratories to Sun Pharmaceuticals *
- Daiichi Sankyo on its acquisition of Plexxikon*
*Denotes experience prior to joining Wilson Sonsini in 2022.
- Privacy Policy
- Terms of Use
- Accessibility